EP 143: Debunking Healthcare's Biggest Myths with Zach Weinberg and Derek Thompson

Drug prices in the U.S. are high to incentivize innovation, with concerns that lowering prices could lead to fewer drugs in the future. The discussion covers drug discovery, manufacturing, and the supply chain, particularly focusing on COVID-19 vaccines and public misconceptions. Derek emphasizes the importance of the NIH for future healthcare advancements, while Zach highlights the impact of mRNA vaccines on vaccine skepticism, noting that COVID-19 had a mortality rate of about 1% during its first wave, especially among older and unhealthy individuals. The rapid development of effective vaccines significantly reduced deaths and hospitalizations, with mRNA vaccines outperforming older technologies in clinical trials.

As COVID mutated, new variants began to escape vaccine efficacy, particularly regarding transmission. The initial justification for vaccine mandates was based on their ability to prevent transmission, but this rationale became outdated, leading to public confusion and diminished support. The shift from societal to personal choice regarding vaccination reflects this change, as the vaccines no longer guaranteed transmission prevention. Frustration with COVID mandates has fueled skepticism about vaccines and mRNA technology, impacting public trust in science. It is crucial to distinguish between policy mistakes and the need to fund scientific advancements, as mRNA research has shown promise beyond COVID.

The historical context of Operation Warp Speed, authorized by Donald Trump, is significant, as the movement that supported it has since polarized against its success. Current budget proposals call for substantial cuts to the NIH and the National Science Foundation, which could hinder future scientific breakthroughs. The analogy of neglecting a house with a termite problem illustrates the long-term consequences of not investing in scientific research. The discussion also considers the rationale for vaccine mandates, particularly for older populations on Medicare, as taxpayers bear the costs of COVID-related hospitalizations.

Misinformation surrounding vaccines is criticized, particularly the discredited 1998 study by Andrew Wakefield that falsely linked vaccines to autism. The negative impact of misinformation on public support for scientific research is emphasized, alongside the distinction between biology research and drug discovery. The conversation underscores the misconception that pharmaceutical companies will resolve major health issues without adequate research funding. Understanding biology can lead to breakthroughs in drug development, as illustrated by GLP-1 drugs derived from Gila monster venom.

Concerns are raised about the current administration's grasp of the importance of biological research and its implications for healthcare policy. The speaker expresses disappointment in the direction of healthcare policy and skepticism towards figures like RFK Jr., while recognizing the expertise of NIH professionals. The conversation critiques gaps in scientific funding and the need for intelligent government action in healthcare reform, proposing that incentivizing innovation through direct payments for products could lead to better outcomes.

The complexities of drug development are examined, including how investors assess expected value based on patient numbers and potential pricing. High drug prices in the U.S. are framed as necessary to incentivize innovation, raising ethical questions about balancing current affordability with future advancements. The discussion highlights significant issues surrounding healthcare costs, emphasizing that less than 10% of healthcare spending is directed towards medicine, with the majority allocated to physician services.

Zach discusses the role of the U.S. in global healthcare innovation, noting that it subsidizes global healthcare through its substantial contributions to drug development. He warns that lowering U.S. drug prices to match European levels could hinder innovation, as the high costs associated with drug development are necessary to incentivize investment. The decline in the number of new drugs approved per billion dollars spent on R&D is alarming, with productivity decreasing significantly over the decades.

The speakers emphasize the need for more efficient breakthrough science to advance health and longevity. They acknowledge that improving economic conditions in America could enhance resources for medical R&D, although the incremental development of new drugs may face challenges. The cost of determining a new drug's potential is substantial, often exceeding $100 million, and the predictive information available before human testing is limited.

Zach expresses skepticism about the development of digital cells for drug testing, arguing that building accurate computer models requires extensive training data, which is often lacking in biological research. He critiques the notion of unrestricted drug testing, referencing historical failures like thalidomide and the role of the FDA in ensuring safety. While advocating for faster scientific progress, he insists that it should not compromise safety standards, arguing that the only viable path to incremental improvements in drug development is through increased funding.